Kendall v. Odonate Therapeutics, Inc.

CourtDistrict Court, S.D. California
DecidedJanuary 11, 2022
Docket3:20-cv-01828
StatusUnknown

This text of Kendall v. Odonate Therapeutics, Inc. (Kendall v. Odonate Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kendall v. Odonate Therapeutics, Inc., (S.D. Cal. 2022).

Opinion

1 2 3 4 5 6 7 8 9 10 11 UNITED STATES DISTRICT COURT 12 SOUTHERN DISTRICT OF CALIFORNIA 13 14 KEVIN KENDALL, individually and on Case No.: 3:20-cv-01828-H-LL behalf of all others similarly situated, 15 ORDER: Plaintiff, 16 v. (1) CERTIFYING CLASS FOR 17 SETTLEMENT PURPOSES; ODONATE THERAPEUTICS, INC., 18 KEVIN C. TANG, MICHAEL HEARNE, (2) PRELIMINARILY APPROVING 19 JOHN G. LEMKEY, CLASS SETTLEMENT; 20 Defendants.

21 (3) APPOINTING CLASS REPRESENTATIVE AND CO- 22 COUNSEL; 23 (4) APPROVING CLASS NOTICE; 24 and 25 (5) SCHEDULING FINAL 26 APPROVAL HEARING 27 [Doc. No. 43.] 28 1 On December 3, 2022, Plaintiff Kevin Kendall filed an unopposed motion for 2 preliminary approval of class action settlement and directing dissemination of notice to 3 the class. (Doc. No. 43.) On January 3, 2022, Defendants Odonate Therapeutics, Inc., 4 Kevin C. Tang, Michael Hearne, John G. Lemkey (collectively, “Defendants”) filed a 5 notice of non-opposition to Plaintiff’s motion. (Doc. No. 46.) The Court held a hearing on 6 the matter on January 10, 2022. Corey D. Holzer, Jennifer Banner Sobers, and Matthew 7 L. Tuccillo appeared on behalf of Plaintiff. Stephan Ryan Benson Richards appeared on 8 behalf of Defendants. For the following reasons, the Court grants Plaintiff’s motion and 9 sets a schedule for further proceedings. 10 Background 11 I. Factual and Procedural Background 12 This is a securities class action against Odonate Therapeutics, Inc. (“Odonate”) and 13 three of its officers under Section 10(b) and 20(a) of the Securities Exchange Act of 1934 14 (the “Exchange Act”) and Rule 10b-5. (Doc. No. 24, SAC ¶¶ 225–41.) The case is 15 brought on behalf of all persons and entities who purchased or otherwise acquired the 16 stock of Odonate between December 7, 2017 and March 25, 2021 (the “Class Period”). 17 (Id. ¶ 217.) Odonate is a pharmaceutical company based in San Diego. (Id. ¶ 2.) 18 Odonate’s single, primary drug candidate is tesetaxel, an orally administered 19 chemotherapy agent developed to treat patients with locally advanced or metastatic breast 20 cancer. (Id. ¶¶ 33–35.) Defendants Tang, Hearne, and Lemkey were officers and 21 collectively the majority shareholder of Odonate during the Class Period. (Id. ¶¶ 1, 3, 19– 22 21.) In December 2017, Odonate initiated a Phase 3 study of tesetaxel. (Id. 36, 57-59.) 23 Plaintiff alleges that between December 8, 2017 and February 23, 2021, Odonate filed for 24 an Initial Public Offering (“IPO”) with the Securities and Exchange Commission 25 (“SEC”) and held multiple subsequent public offering of its shares in order to raise funds 26 for Odonate’s continued operations and tesetaxel’s study. (Id. ¶¶ 37–38, 188.) Plaintiff 27 alleges that through its IPO and subsequent offerings, Odonate raised $394.6 million in 28 gross proceeds and $369.78 million in net proceeds. (Id. ¶ 39.) 1 Plaintiff alleges Odonate’s value proposition to investors was tesetaxel. (Id. ¶ 36.) 2 Plaintiff alleges that during the Class Period, significant safety concerns regarding 3 tesetaxal arose during the Phase 3 study, which Plaintiff alleges Defendants were aware 4 of but did not disclose to investors or the public. (Id. ¶¶ 5–7, 40.) Plaintiff also alleges 5 that during the class period, Defendants made false and misleading statements containing 6 misrepresentations and omissions regarding the tesetaxel Phase 3 study, patient outcomes 7 and experiences while using tesetaxel, and the likelihood of tesetaxels’ approval by the 8 FDA. (Id. ¶¶ 56–181.) On March 22, 2021, Odonate issued a press release announcing it 9 was discontinuing tesetaxel’s development following feedback from the U.S. Food and 10 Drug Administration (“FDA”) that the clinical data package for tesetaxel was unlikely to 11 support FDA approval. (Id. ¶ 168.) On March 25, 2021, Odonate filed a Form 8-K with 12 the SEC providing more details about Odonate’s discontinuation of tesetaxels’ 13 development and the wind-down of Odonate’s operations. (Id. ¶ 170.) Plaintiff alleges 14 Odonate’s stock price fell dramatically following the press release and Form 8-K filing. 15 (Id. ¶¶ 169, 171.) 16 On September 16, 2020, Plaintiff filed a class action complaint against Defendants. 17 (Doc. No. 1.) On December 14, 2020, the Court granted Plaintiff’s unopposed motion to 18 appoint Plaintiff as Lead Plaintiff and approval of Plaintiff’s selection of counsel. (Doc. 19 No. 11.) On February 16, 2021, Plaintiff filed the first amended class action complaint. 20 (Doc. No. 21.) On April 13, 2021, Plaintiff filed the second amended class action 21 complaint. (Doc. No. 24.) On May 13, 2021, Defendants filed a motion to dismiss 22 Plaintiff’s second amended complaint. (Doc. No. 25.) On August 4, 2021, the Court 23 denied Defendants’ motion to dismiss. (Doc. No. 36.) On September 3, 2021, Defendants 24 filed their answer to Plaintiff’s second amended complaint. (Doc. No. 37.) 25 On September 20, 2021, the parties held a virtual mediation before Michelle 26 Yoshida, Esq. of Phillips ADR Enterprise, but were unable to reach a settlement that day. 27 (Doc. No. 43 at 4.) Over the next three weeks the parties continued negotiations and 28 ultimately came to an agreement to settle the action in principle. (Id.) On October 19, 1 2021, the parties executed a memorandum of understanding regarding the settlement in 2 principle. (Id.) On October 26, 2021, the parties filed a joint motion to enter a stipulation 3 to stay the proceedings pending settlement. (Doc. No. 39.) On November 3, 2021, the 4 Court granted the parties’ joint motion to stay the proceedings. (Doc. No. 39.) The Court 5 also ordered Plaintiff to file a motion for preliminary approval of the class action 6 settlement on or before January 31, 2022. (Id.) On December 3, 2021, Plaintiff filed the 7 present unopposed motion seeking (1) preliminary approval of the proposed class action 8 settlement; (2) preliminary certification of the settlement class, appointment of Lead 9 Plaintiff as representative of the settlement class, and appointment of Co-Lead Counsel as 10 counsel for the settlement class; (3) approval of the form and manner of giving notice to 11 the class; and (4) a final approval hearing and a schedule for various deadlines. (Doc. No. 12 43.) 13 II. Proposed Settlement 14 Under the proposed settlement, Defendants will pay the settlement amount of 15 $12,750,000.00. (Doc. No. 43-2, Tuccillo Decl. Ex. 1 ¶¶ 1.32, 2.0 (“Stipulation”).) The 16 settlement will be distributed to class members pro rata in accordance with a plan of 17 allocation that has been designed by Co-Lead Counsel. (Id. ¶ 6.7; Ex. B1 at 6.) Under the 18 plan of allocation, a Recognized Loss amount for each share purchased within the Class 19 Period will be calculated based when the stock was purchased or acquired and, if 20 applicable, sold. (Id.; Ex. B1 at 14–15.) The Recognized Loss is the basis for how the 21 settlement fund will be proportionately allocated to class members. (Id. at 12.) The 22 Recognized Loss is intended to estimate the alleged artificial inflation of the price of 23 Odonate stock at different times during the Class Period due to alleged 24 misrepresentations by Defendants. (Id. at 12.) No distribution will be made to class 25 members who would receive a distribution of less than $10.00. (Id. at 16.) Any remaining 26 funds in the settlement fund after at least six (6) months after the initial distribution will 27 be used first, to pay any amounts mistakenly omitted from the initial disbursement; 28 second, to pay any additional settlement administration fees, costs, and expenses; and 1 third, to make a second distribution to class members who cashed their checks from the 2 initial distribution. (Id. at 17.) None of the funds will revert back to Defendants. (Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
General Telephone Co. of Southwest v. Falcon
457 U.S. 147 (Supreme Court, 1982)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Philip Rannis v. Peter Recchia
380 F. App'x 646 (Ninth Circuit, 2010)
In Re Bluetooth Headset Products Liability
654 F.3d 935 (Ninth Circuit, 2011)
Staton v. Boeing Co.
327 F.3d 938 (Ninth Circuit, 2003)
Rodriguez v. West Publishing Corp.
563 F.3d 948 (Ninth Circuit, 2009)
In Re Tableware Antitrust Litigation
484 F. Supp. 2d 1078 (N.D. California, 2007)
Muhammed Abdullah v. U.S. Security Associates, Inc.
731 F.3d 952 (Ninth Circuit, 2013)
Hanlon v. Chrysler Corp.
150 F.3d 1011 (Ninth Circuit, 1998)
Alberto v. GMRI, Inc.
252 F.R.D. 652 (E.D. California, 2008)
In re Juniper Networks, Inc. Securities Litigation
264 F.R.D. 584 (N.D. California, 2009)
Class v. City of Seattle
955 F.2d 1268 (Ninth Circuit, 1992)
Ikonen v. Hartz Mountain Corp.
122 F.R.D. 258 (S.D. California, 1988)

Cite This Page — Counsel Stack

Bluebook (online)
Kendall v. Odonate Therapeutics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/kendall-v-odonate-therapeutics-inc-casd-2022.